Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine (Q28253310)

https://api.crossref.org/works/10.1080/14756360802610761

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 April 2017

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

New perspectives into the molecular pathogenesis and treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Adapting the GLP-1-signaling system to the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Berberine synergy with amphotericin B against disseminated candidiasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

The anti-inflammatory potential of berberine in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Effects of berberine on glucose metabolism in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Efficacy of berberine in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

The statistical-thermodynamic basis for computation of binding affinities: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Evaluation of docking performance: comparative data on docking algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Comparison of topological, shape, and docking methods in virtual screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

Molecular recognition of ligands in dipeptidyl peptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14756360802610761